MARKET WIREInvesting.com • 22h ago
BioCardia president and CEO Peter Altman buys $475 in BCDA sharesInvesting.com report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
Why BCDA Stock surged +4.75% Today — RQD Quant Desk Flash
$0.90 +4.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.91
BioCardia Inc. (BCDA) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $13.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BCDA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BCDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, BioCardia Inc. (NASDAQ: BCDA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.90 (+4.75% 1D, market cap $13.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BCDA ranks #548 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BCDA compare to ATYR and ABOS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BCDA carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ATYR (aTyr Pharma Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M) and ABOS (Acumen Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M). Among the 5-stock peer group, BCDA leads on earnings multiple (N/A) while BCDA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BCDA?
▼
Per BCDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000925741), BioCardia Inc. generated $23.2M in revenue (+3.5% YoY), -$8.2M in net income, and -$7.4M in free cash flow against $3.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.91 (+0.67%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BCDA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY BCDA SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (24% of score)
FRED Regime × Technicals: 14% of 52W Range • RSI-14 at 40 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.99+5.1% Next Q
45
Q2 (-2Q)Grade D$1.04-11.5% Next Q
42
Q3 (-1Q)Grade D$0.92-2.2% Next Q
40
CurrentGrade D-$0.90-8.1% Hist 90D α
37
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BCDA Turnaround Squeeze
While BCDA currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.04) and Max Pain ($0.95) forces dealer call-delta covering toward $1.89.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BCDA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BCDA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BCDA Stock surged +4.75% Today — RQD Quant Desk Flash
BioCardia Inc. (BCDA) surged +4.75% to $0.90, trading at 14% of its 52-week range ($0.75 – $1.8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 14% of its 52-week range ($0.75 – $1.8) with RSI-14 at 40 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.90 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BCDA Headlines & Catalysts
MARKET WIREStock Titan • 1d ago
FDA agrees BioCardia's heart-failure trial may support approval of its cell treatment.Stock Titan report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREkalkine.ca • 1d ago
BioCardia (NASDAQ:BCDA) Penny Stock Up 6% Pre-Market on an FDA Procedural Stepkalkine.ca report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHQuiver Quantitative • 1d ago
BioCardia Announces FDA Acceptance of Helix Catheter De Novo Pre-Submission for Marketing ClearanceQuiver Quantitative report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
At $0.95 per share, BioCardia (BCDA) CEO buys 500 shares across two purchases.Stock Titan report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A device for heart treatments has data from 15 trials and nearly 500 patients. FDA accepted its package.Stock Titan report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHInvesting.com India • 1d ago
FDA accepts BioCardia pre-submission for Helix catheter By Investing.comInvesting.com India report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHKalkine Media • 1d ago
FDA Accepts BioCardia's De Novo Pre-Submission for Helix Catheter, Review Scheduled This QuarterKalkine Media report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 15d ago
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this QuarterSUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced t
RISK WATCHBenzinga • 15d ago
BioCardia Receives FDA Acceptance For Its Pre-Submission Package For Marketing Clearance Of Its Helix Catheter For Therapeutic And Diagnostic Agent DeliveryBioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BCDA)
- ✓Walkthrough of BCDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BCDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.35%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.92H $0.92L $0.86C $0.90VOL 79.3K
RES: $1.49SUP: $0.86SMA50: $1.04SMA200: $1.07
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BCDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +3.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on BCDA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BCDA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BCDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BCDA)
Health Care Rank #548 of 1015
⚔️ ATYR vs BCDA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BCDA vs. ATYR, ABOS, DYAI, PASG)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, BioCardia Inc. (BCDA) ranks #548 by composite RQD confidence (37/100, grade D-) and #863 by equity capitalization ($13.0M). Within this direct 5-issuer industry benchmark cohort, BCDA leads on earnings valuation at N/A trailing P/E, while BCDA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATYR currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with BCDA at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BCDA
ACTIVE
BioCardia Inc. | D- | 37/100 | — | — | -35.0% | +4.75% | $13.0M | Benchmark Subject |
| ATYR aTyr Pharma Inc. | D | 46/100 | — | — | -35.0% | +27.33% | $12.4M | /atyr-vs-bcda → |
| ABOS Acumen Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | +14.09% | $15.2M | /abos-vs-bcda → |
| DYAI Dyadic International Inc. | E | 31/100 | — | 24.9% | -35.0% | -1.10% | $15.2M | /dyai-vs-bcda → |
| PASG Passage Bio Inc. | E | 34/100 | — | — | -35.0% | -3.77% | $11.1M | /pasg-vs-bcda → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000925741 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioCardia Inc. (BCDA) reported GAAP revenue of $23.2M (+3.5% vs. FY2024 revenue of $22.4M , and -28.9% cumulative change since FY2023) , GAAP net income of -$8.2M, operating cash flow of -$7.4M, and free cash flow of -$7.4M (+5.7% YoY). On the balance sheet, BCDA closed FY2025 with $3.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $23.2M | -$8.2M | -$7.4M | -$7.4M | $3.4M | — |
| FY2024 (FY) | 2024-12-31 | $22.4M | -$7.9M | -$7.9M | -$7.9M | $3.7M | — |
| FY2023 (FY) | 2023-12-31 | $32.6M | -$11.6M | -$10.0M | -$10.0M | — | — |
3. BCDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BCDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, BioCardia Inc. (NASDAQ: BCDA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.90 (+4.75% 1D, market cap $13.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BCDA ranks #548 in composite RQD confidence.
How does BCDA compare to ATYR and ABOS in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BCDA carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ATYR (aTyr Pharma Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M) and ABOS (Acumen Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M). Among the 5-stock peer group, BCDA leads on earnings multiple (N/A) while BCDA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BCDA?
Per BCDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000925741), BioCardia Inc. generated $23.2M in revenue (+3.5% YoY), -$8.2M in net income, and -$7.4M in free cash flow against $3.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BCDA trading relative to its 50-day, 200-day, and 52-week technical levels?
BCDA last traded at $0.90 (+4.75% on volume of 81,694 shares), positioning the stock -13.46% below its 50-day simple moving average ($1.04) and -15.89% below its 200-day simple moving average ($1.07). Across its 52-week range of $0.75 to $1.80, BCDA sits at the 14.3% percentile with a 14-day RSI of 40.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.01).
ROARABLE RATING BRIEF • RQD 37/100 (D-)
✓ SEC XBRL & RQD VERIFIED
BCDA — BioCardia Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
BioCardia Inc. (BCDA) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.90 (+4.75% 1D, market capitalization $13.0M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
BioCardia Inc. (BCDA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BioCardia Inc. (BCDA) reported $23.2M in annual revenue (up from $22.4M in FY2024, +3.5% YoY) and -$8.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($32.6M revenue, -$11.6M net income) through FY2025, BCDA scaled operating cash flow to -$7.4M and free cash flow to -$7.4M, backed by $3.4M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.75 – $1.80 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies are — Sector correlation data is — The main 2nd-order watch item an investor should track is the regulatory path: per the news wire, the FDA acceptance and procedural steps are the primary ripple channel, since clearance or delay would affect the company directly without any identified supply-chain transmission.
- Key Question #1: Can BCDA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $23.2M and free cash flow of -$7.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is BCDA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
BCDA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for BioCardia Inc. (BCDA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Investing.com • 22h ago
BioCardia president and CEO Peter Altman buys $475 in BCDA shares Investing.com report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
FDA agrees BioCardia's heart-failure trial may support approval of its cell treatment. Stock Titan report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 1d ago
BioCardia (NASDAQ:BCDA) Penny Stock Up 6% Pre-Market on an FDA Procedural Step kalkine.ca report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Quiver Quantitative • 1d ago
BioCardia Announces FDA Acceptance of Helix Catheter De Novo Pre-Submission for Marketing Clearance Quiver Quantitative report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
At $0.95 per share, BioCardia (BCDA) CEO buys 500 shares across two purchases. Stock Titan report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A device for heart treatments has data from 15 trials and nearly 500 patients. FDA accepted its package. Stock Titan report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Investing.com India • 1d ago
FDA accepts BioCardia pre-submission for Helix catheter By Investing.com Investing.com India report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Kalkine Media • 1d ago
FDA Accepts BioCardia's De Novo Pre-Submission for Helix Catheter, Review Scheduled This Quarter Kalkine Media report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BCDA Bull vs. Bear Conversation Board — What's Your Call at $0.90?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BCDA 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $1.10 (+27.9%)
📌 Pinned Debate FDA acceptance of the Helix Catheter pre-submission and a reported FDA view that the heart-failure trial may support approval could be
Picked up a starter position in BCDA in my $100K Virtual Cash book at $0.86. FDA acceptance of the Helix Catheter pre-submission and a reported FDA view that the heart-failure trial may support approval could be catalysts for the shares.. Trading inside a $0.75–$1.80 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.
RetailWhale_TX 🐂 BULL
@BearTrap_Alert Shorting a 5/20 institutional whale-flow stock at $0.86 is dangerous when funds are rotating into Health Care.
BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH
🎯 Target: $0.72 (-16.3%)
Spot @ $0.86 The company reports $0.0M revenue, -35% ROIC, an Altman Z-Score of 2.5, and a Piotroski F-Score of 2/9, with cash of $2.5M against FY 2
Careful chasing BCDA at $0.86. The company reports $0.0M revenue, -35% ROIC, an Altman Z-Score of 2.5, and a Piotroski F-Score of 2/9, with cash of $2.5M against FY 2025 free cash outflows of -$7.4M.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.72 on multiple compression.